Monday, 28 January 2019

Liquid Biopsy Market Size is Estimated to Reach USD 3,051.1 Million by 2025

New York City, 28 January 2019: Liquid Biopsy Market is anticipated to reach USD 3,051.1 million by 2025 according to a new report published by Polaris Market Research. In 2017, by biomarker type, Circulating Tumor Cells (CTC) segment was observed to capture the largest market share in terms of revenue. Regionally, North America liquid biopsy market accounted for the majority share.

Liquid Biopsy can be described as a traditional technique that is used in diagnosis of cancer at an early stage. It is also known as fluid biopsy or fluid phase biopsy. It is largely a non-invasive technique, which helps in proper tracking of tumors and mutations over a duration of time. Usage of these provides doctors with a range of information about the tumor’s future. Despite being a revolutionary technique, liquid biopsy has multiple challenges in terms of adoption over tissue biopsy.
Request For Sample
The liquid biopsy market is primarily driven by the increasing cases of patients being detected with various types of cancer. Also, considering number of free trails coupled with rising demand for liquid biopsy with minimal invasive surgeries is expected to enhance the market growth during forecast period. Also, liquid biopsy is observed to be the fastest emerging substitute for tissue biopsy due to reduced number of surgical invasions. Furthermore, increasing trend of strategic mergers and acquisitions by key players to support their focus on continuous research and development activities also positively impacts the liquid biopsy market.

On the basis of technology type, the report on global liquid biopsy market covers single gene analysis (PCR Microarrays), and multi-gene-parallel analysis (NGS). NGS multiplex testing helps in diagnosis of multiple diseases at a single time, while PCR helps in analyzing the mutation among genes. Based on sample type, the global liquid biopsy market is sub-segmented into blood, urine, saliva, and other body fluid. Blood sample is the most common sample type that is used by doctors for proper analysis as blood contains cell free DNA, circulating cell, and exosomes that can be detected easily eventually helping in easy diagnosis of the cancer cell in the human body. Moreover, saliva and other body fluids are other sampling types in this market which have significant market share.

Based on the biomarker type, the global liquid biopsy market is further segmented into exosomes, Circulating Tumor Cells (CTC), and Circulating tumor DNA (ctDNA). CTC biomarker is expected hold the largest market share owing to its high awareness, and effective results for tracking the cancer cells in human body. In addition, it facilitates early detection of cells which in turn helps for appropriate diagnosis and clinical decisions related to detected cancer in the initial stage itself.

The global liquid biopsy market report covers molecular health monitoring, therapy selection for other meta cancer, and therapy selection for MBS applications. Various therapy for treating meta cancer application is observed to hold major market share owing to the rising number of metastatic cancer incidences, and rising number of therapies for its treatment. Additionally, increase in treatment commercialization for metastatic cancers to also drive growth in this market.

North America region is observed to hold the dominating position as per geography in the liquid biopsy market during the forecast period. Factors such as increasing advanced accessibility for the diagnosis of cancer, and increasing number of patients suffering from cancer promote the growth of this market. Meanwhile, Asia Pacific is supposed to grow at a faster rate during the forecast period.

The major players operating in the liquid biopsy market include Roche Diagnostics, Illumina, Inc., Bio-Rad Laboratories Inc., Myriad Genetics, Inc., Menarini Silicon Biosystems, Genomic Health, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Biocept, Inc., Trovagene, Inc., RainDance Technologies, Inc., Guardant Health, Inc., and MDx Health SA.

Browse Full Research Report on "Liquid Biopsy Market" @ https://www.polarismarketresearch.com/industry-analysis/liquid-biopsy-market/

Orthopedic Implants Market Size is Estimated to Reach USD 6,558.3 Million by 2025 at a CAGR of 4.84%

New York City, 28 January 2019: Orthopedic Implants Market is anticipated to reach USD 6,558.32 million by 2025 according to a new report published by Polaris Market Research. In 2017, application type, knee orthopedic implants segment captures the largest market shares in terms of revenue and hold the major share in the market. Regionally, North America accounted for the major share in the orthopedic implants market.

The global orthopedic implants market growth is primarily driven by the increasing number of the geriatric population globally and increased life expectancy that has increased the risk of osteoporosis and osteoarthritis. For instance, according to WHO the average life expectancy in Japan is approximately 83.7 years, and 82.3 years in South Korea. Additionally, increased government expenditure on medical device industry, and the development of favorable government regulations for the use of these orthopedic implants to influence the market growth during this period. Moreover, the changing lifestyle, rising number of sports injuries, and trauma cases is also an important factor that is positively affecting the market. On the other hand, the increasing number of minimally invasive surgery for treating various spinal injuries and spinal disorders. However, high treatment cost of orthopedic implants, and stringent regulatory for the use of various orthopedic implants to hinder the growth of the orthopedic implants market during the forecast period.

Request For Sample
On the basis of application type, the global orthopedic implants market is segmented as, spinal orthopedic implants, hip orthopedic implants, knee orthopedic implants, craniomaxillofacial orthopedic implants, dental orthopedic implants, and S.E.T (Sports Medicine, Extremities, Trauma) orthopedic implants.

By geography, the global orthopedic implant market is segmented into five major regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of geography, North America dominates the entire orthopedic implant market. The growth in the market is majorly driven by the increasing healthcare expenditure by the local governments and developed healthcare infrastructure in the U.S. and Canada. Furthermore, the rising prevalence of the geriatric population in this region to spur the orthopedic implant market in North America.

The leading companies operating in this market icludes Medtronic plc, Zimmer Biomet Holdings, Inc., Aesculap Implants Systems, DePuy Synthes, BioTek Instruments Inc., Conmed Corporation, The Orthopedic Implant Company, Smith & Nephew plc, Stryker Corporation, Wright Medical Group N.V., NuVasive Inc., and Arthrocare Crporation.

Key Findings from the study suggest implants available in the market are continuously concentrating on the technological advancements. Companies while developing new implant device which consider the factors such as increasing awareness and acceptance for orthopedic implants, and effective treatment for various orthopedic disorders in the developing countries. North America is presumed to dominate the global orthopedic implants market over the forecast years and Asia Pacific region shows signs of high growth owing to the booming economies of India, and China.

Get Full Research Report about "Orthopedic Implants Market" @ https://www.polarismarketresearch.com/industry-analysis/orthopedic-implants-market/

Breast Cancer Therapy Market worth USD 29.6 Billion by 2026 at a CAGR of 10.3%

New York City, 28 January 2019: Breast Cancer Therapy Market is anticipated to reach USD 29.6 Billion by 2026 according to a new research published by Polaris Market Research. In 2017, the targeted therapy segment dominated the global market, in terms of revenue.

Breast cancer is a disorder which is observed as malignant cell growth in the breast area. Such cancer can start at the breast tissue, ducts, or the lobules. In general, cancers developing from lobules are known as lobular carcinomas while cancer developing from the ducts are known as ductal carcinomas. The symptoms of cancer include dimpling of the skin, lumps, alteration in the breast size and impeding of fluid coming from breast. Generally, breast cancer is observed as the common disease in women over the age of 50. Moreover, the breast cancer is second most common disorder among all cancer types. This disease can be diagnosed and controlled by imaging test, physical tests, biopsy and appropriate care.

Global Breast Cancer Therapies Market Share, By Therapy Type, 2017 - 2026 

Request For Sample
The global breast cancer therapies market is majorly driven by increasing occurrence of breast cancer cases across the globe. Rising number of breast cancer cases are related with early menarche, protracted exposure to endogenous estrogens, late menopause and late stage at first childbirth which all are anticipated to render high impact on the market growth. In addition, launch of several screening and diagnostic programs and increasing advancement in technology are other factors expected to make a remarkable growth in the market. Moreover, increasing occurrence of obesity in women after menopause, increasing consciousness regarding breast cancer, and lifestyle risk factors (alcohol consumption and smoking) are other circumstances expected to drive the growth in global breast cancer therapies market.

Geographically, North America accounted for the largest share in the global breast cancer therapies market in 2017. The dominance is majorly owing to the increasing R&D funding through private and public organizations along with growing prevalence of breast cancer in the region. Moreover, increasing geriatric population majorly in U.S. and, breast feeding termination at an early stage are factors stimulating the risk factors for breast cancer development which in turn is expected to support the growth of breast cancer therapies market in North America region. Asia Pacific breast cancer therapies market is expected to grow at significant rate during the forecast period due to increasing occurrence of disease coupled with increasing rate of lifestyle changes and health risks associated with it. Moreover, increasing adoption of technology, refining economic settings, and rising awareness regarding disease preventions are other factors boosting the breast cancer therapies market growth across Asia Pacific region.

The leading companies profiled in the Breast Cancer Therapies Market report include AstraZeneca, Bayer AG, Danaher, Bristol Myers Squibb, Eisai Co., Ltd., Merck & Co., Novartis AG, Novocure, Pfizer Inc., and F. Hoffmann-La Roche AG.

Get more insights about "Breast Cancer Therapy Market" @ https://www.polarismarketresearch.com/industry-analysis/breast-cancer-therapy-market/

Friday, 25 January 2019

Disposable Syringes Market Size Estimated To Reach USD 11.19 Billion By 2026 at a CAGR of 5.6%

New York City, 25 January 2019: Disposable Syringes Market is anticipated to reach over USD 11.19 billion by 2026 according to a new research published by Polaris Market Research. In 2017, the therapeutic injections dominated the global Disposable Syringes market, in terms of revenue. North America is expected to be the leading contributor to the global market revenue in 2017. Disposable Syringes are the syringes manufactured from plastic, which are used in replacing the useable syringes in the coming years. These syringes are considered to be the cost effective, and also help in reducing the cost of treatment and chances of infection to the individual.

The Disposable Syringes market is primarily driven by the increasing number increasing government initiatives and regulation that has promoted the market growth during the forecast period. Additionally, increasing activities by various NGO’s that create awareness for the use of disposable syringes, and need to control the spread of the life taking diseases such as HIV to also boost the Disposable Syringes market growth in the coming years. Additionally, the continuous product development by the manufacturing, and their efforts to tap the potential eastern market to support the Disposable Syringes market growth during the forecast period.

Request For Sample
North America generated the highest revenue in the Disposable Syringes market in 2017, and is expected to be the leading region globally during the forecast period. The North Americas Disposable Syringe Market is primarily driven by the rising prevalence of infections that need to be treated with the help of therapeutic injection. Additionally, presence of key players in this region that are focusing on product development, and increasing number of clinical trials that has promoted the growth of this market in the region. Moreover, Europe being the second largest contributor in the disposable syringe market owning to the stringent government which promoted the used of safety engineered products.

The key players operating in the Disposable Syringes market include Fresenius Kabi AG, Becton, Dickinson and Company, Baxter International, Inc., UltiMed, Inc. Flextronics International Vita Needle Company, Terumo Corporation, Novo Nordisk, Henke-Sass, Wolf, Covidien, Braun Medical, Inc., Retractable Technologies, Inc., among others. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers.

Browse More Information on "Disposable Syringes Market" @ https://www.polarismarketresearch.com/industry-analysis/disposable-syringes-market/

Sleep Disorder Market Size Estimated To Reach USD 95.66 Billion by 2026 at a CAGR of 8.0%

New York City, 25 January 2019: Sleep Disorder Market size is anticipated to reach over USD 1.31 billion by 2017. In 2017, the sleep apnea devices dominated the global market, in terms of revenue. Asia-Pacific is expected to be the Fastest growing contributor to the global market revenue in 2017.

Sleep is complex neurological state that helps in restoring energy level in the body. Alterations in the quality and pattern if sleep may cause sleep disorder. Sleep disorder is defined as a sleep problem, which is characterized by snoring, insomnia, depression, and sleep apnea. Recently, in a study it is found that the approximately more than 75% of Americans from the age of 25 to 59 suffer from sleep disorder in the U.S. Sleep disorder is basically characterize by the difficulty in falling asleep, daytime fatigue, lack of concentration, anxiety, and depression.

Request For Sample
The sleep disorder market is primarily driven by the increasing number individual population suffering from various mental disorders, and rising awareness for the treatment of sleep disorders in the coming years. Furthermore, the changing life style of the people, and rising preference to the sedentary life style to also support the market growth in the coming years. Additionally, changing working culture, increasing geriatric population, and lack of quality sleep to also boost the market growth during the forecast period.

On the other side, increasing morbidity due to sleep disorder has increased the healthcare cost, and related side effects of the drugs, and increasing patent expiries that are used in treating sleep disorders which would impede the market growth during the forecast period.  The treatment for include medication, better sleeping habits, and devices. Medicines such as, Hetlioz (tasimelteon) by Vanda Pharmaceuticals, Intermezzo (zolpidem tartrate sublingual tablet) by Transcept Pharmaceuticals, and Silenor (doxepin) by Somaxon Pharma are some of the FDA approved drugs that are observed to be beneficial during the treatment of sleep disorders.

The industry is segmented on the basis of disorder type, device, treatment, and geography. Based on disorder type, the market is bifurcated into sleep apnea, sleep breathing disorders, insomnia, hypersomnia, circadian rhythm disorders, parasomnia, and sleep movement disorders. on the basis of devices, the market is segmented into sleep apnea devices, sleep laboratories, and mattresses & pillows. By Treatment, the market is further bifurcated as psychiatric treatment, behavioral treatment, cognitive behavioral therapy, and medication therapy.

The market for sleep disorder in North America generated the highest revenue in 2017, and is expected to be the leading region globally during the forecast period. High number of patient population suffering the sleeping disorders is the primary factor accountable for the highest market growth. According to the US Department of Health and Human Services reports, approximately 20% Americans are suffering from sleep disorder. Thus, increasing demand for early treatments along with increasing patient pool, and growing patient awareness for proper diagnosis methods are factors boosting the growth in North America.

Asia Pacific is estimated to be the fastest growing region in terms of revenue. Growing awareness about sleep disorders and developing healthcare infrastructure are some of the factors that are projected to generate lucrative opportunities for the market in APAC.

The major key players operating in the Sleep Disorder industry include GlaxoSmithKline plc, Becton Dickson and Company, Cardinal Health, Natus Medical Incorporated Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., and Teva Pharmaceutical Industries Ltd. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers.

Polaris Market Research has segmented the global sleep disorders market on the basis of disorder, devices, treatment and region:

Sleep Disorder by Disorder Outlook (Revenue, USD Million, 2015 – 2026)
  •     Insomnia
  •     Hypersomnia
    1.         Insufficient Sleep Syndrome
    2.         Narcolepsy
  •     Sleep Apnea
  •     Sleep Breathing Disorders
  •     Circadian Rhythm Disorders
  •     Parasomnia
    1.         Sleep Eating Disorder
    2.         Sleep Terror
    3.         REM Sleep Behavior Disorder
    4.         Others
  •     Sleep Movement Disorders
    1.         Restless Leg Syndrome
    2.         Sleep Leg Cramps
Sleep Disorder Devices Outlook (Revenue, USD Million, 2015 – 2026)
  •     Sleep Apnea Devices
  •     Sleep Laboratories
  •     Mattresses & Pillows
Sleep Disorder Treatment Outlook (Revenue, USD Million, 2015 – 2026)
  •     Psychiatric Treatment
  •     Behavioral Treatment
  •     Cognitive Behavioral Therapy
  •     Medication Therapy
    1.         Prescription Drugs
    2.         OTC Drugs
    3.         Herbal Drugs
Sleep Disorder Regional Outlook (Revenue, USD Million, 2015 – 2026)
  •     North America
  1.         U.S.
  2.         Canada
  •     Europe
  1.         Germany
  2.         UK
  3.         France
  4.         Italy
  5.         Spain
  6.         Belgium
  7.         Russia
  8.         Netherlands
  9.         Rest of Europe
  •     Asia-Pacific
  1.         China
  2.         India
  3.         Japan
  4.         Korea
  5.         Singapore
  6.         Malaysia
  7.         Indonesia
  8.         Thailand
  9.         Philippines
  10.         Rest of Asia-Pacific
  •     Latin America
  1.         Brazil
  2.         Mexico
  3.         Argentina
  4.         Rest of LATAM
  •     Middle East & Africa
  1.         UAE
  2.         Saudi Arabia
  3.         South Africa
  4.         Rest of MEA

Medical Disposable Market Size Estimated to Reach USD 365.1 Billion by 2026 at a CAGR of 6.1%

New York City, 25 January 2019: Medical Disposable Market is anticipated to reach over USD 365.1 billion by 2026 according to a new research published by Polaris Market Research. In 2017, the drug delivery dominated the worldwide medical disposable industry. Asia-Pacific is anticipated to be the leading contributor to the global market revenue in 2017. The upward momentum of medical disposable in the hospitals, outpatient facility and other healthcare providers. The medical disposable market is primarily driven by increasing number of elderly populations, increasing need to limit the causes of infection, better performance, cost reliability, shelf life, and material. The reusable devices are considered to be relatively inexpensive in many different types, and increasing volume of production by the key players globally would also influence the market growth in the coming years.

Increasing number of technologically advanced products, and continuous research and development to also drive the market growth. Furthermore, increasing awareness in the patients for the use of medical disposable devices to also boost the market growth in the coming years. Also, increasing number of chronic diseases across the globe would also boost the market growth in the coming years.

Global Medical Disposable Market (USD Billion) & Y-o-Y Growth (%) 

Global Medical Disposable Market (USD Billion)
Request For Sample
Based on the product type the medical disposable market is segmented as Wound Management, Drug Delivery, Dialysis, Nonwoven Incontinence, Respiratory Supplies, Diagnostic and Laboratory, and Sterilization. Similarly, on the basis of raw material, the market is segmented as Paper and Paperboard, Plastic Resin, Nonwoven Material, Metals, Glass, and Rubber. Plastic Resin is expected to be the fastest growing segment owning to its various application. End user for the medical disposable devices include Hospitals, Outpatient/Primary Care Facilities, and Home Healthcare.

North America generated the highest revenue in the Medical Disposable market in 2017, and is expected to be the leading region globally during the forecast period. Increasing demand healthcare facilities, increasing number of geriatric populations, and continuous mergers and acquisitions of the key players in the U.S. and Canada. Asia Pacific to also boost the market growth in coming years. The developing healthcare infrastructure of the countries in this region to be the major factor promoting the growth of this market during the forecast period.

The key players operating in the Medical Disposable market include Johnson & Johnson Services, Inc., 3M, Abbott Laboratories, Medtronic Plc., B. Braun Melsungen AG, Bayer AG, Smith and Nephew Plc., Medline Industries, Inc., Cardinal Health, and Becton, Dickinson & Company. The industry participants launch novel products with collaboration and partnership agreements with other companies to innovate and launch new products to meet the increasing needs and requirements of consumers.

Read more on "Medical Disposable Market" @ https://www.polarismarketresearch.com/industry-analysis/medical-disposable-market/

Mesenchymal Stem Cells Market Size Estimated to Grow at a CAGR of 7.0% 2018 to 2026

New York City, 25 January 2019: Mesenchymal Stem Cells Market is anticipated to grow at a CAGR of 7.0% from 2018 to 2026 according to a new research report published by Polaris Market Research. The market was valued at USD 1,335.1 million in 2017 and is estimated to reach USD 2,518.5 Million by 2026. In 2017, the drug discovery application dominated the market, in terms of revenue. North America region is observed to be the leading contributor in the global market revenue in 2017.

Mesenchymal stem cells are adult stem cells, which are traditionally found in the bone marrow. However, they can also be parted from other available tissues including peripheral blood, cord blood, fallopian tube. These stem cells mainly function for the replacement of damaged cell and tissues. The potential of these cell is to heal the damaged tissue with no pain to the individual. Scientists are majorly focusing on developing new and innovative treatment options for the various chronic diseases like cancer. Additionally, the local governments have also taken various steps for promoting the use of these stem cells.
Request For Sample
The global mesenchymal stem cells market growth is primarily driven by the increasing demand for these stem cells as an effective treatment alternative for knee replacement in the recent past. Furthermore, increasing elderly population across the globe, and rising prevalence of various chronic diseases including cancer, autoimmune diseases, bone and cartilage diseases are factors expected to boost the market growth during the forecast period. In addition, effective government policies, and funding for research and development would positively influence the market growth over coming years. However, some of the political point of views, and higher cost of treatment by using mesenchymal stem cells might restraint the growth during the forecast period.


Increasing demand for better healthcare facilities, rising geriatric population across the globe, and continuous research and development activities in this area by the key players is expected to have a positive impact on the growth of Mesenchymal Stem Cells market. North America generated the highest revenue in 2017, and is expected to be the leading region globally during the forecast period.  The Asia Pacific market is also expected to witness significant market growth in coming years. Developing healthcare infrastructure among countries such as China, India in this region is observed to be the major factor promoting the growth of this market during the forecast period.

The major key players operating in the industry are Cell Applications, Inc., Cyagen Biosciences Inc. Axol Bioscience Ltd., Cytori Therapeutics Inc., Stem cell technologies Inc., Celprogen, Inc.  BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc. These companies launch new products and undertake strategic collaboration and partnerships with other companies in this market to expand presence and to meet the increasing needs and requirements of consumers.

Browse In-Depth Research Report on "Mesenchymal Stem Cells Market" @ https://www.polarismarketresearch.com/industry-analysis/mesenchymal-stem-cells-market/